Biomarker ID | 517 |
PMID | 20171670 |
Year | 2010 |
Biomarker | prostate specific antigen |
Biomarker Basis | Concentration Based (ng/ml) |
Biomolecule | Protein |
Source | Serum |
Subjects | Humans |
Regulation | Upregulated in PCa |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways include:-ID regulation of gene expression,Prostate cancer, Androgen receptor proteolysis and transcription regulation, Androgen receptor signaling, proteolysis, and transcription regulation, Insulin-like growth factor (IGF) activity regulation by insulin-like growth factor binding proteins (IGFBPs) |
Experiment | Prostate Cancer Vs Benign Sample |
Type of Biomarker | Diagnostic |
Cohort | 2036 men were screened for prostate cancer, and 322 were reccomended for biopsy. Out of these, 74 men complied out of which, 3 had a total PSA of 2.5 to 10 ng/ml and nonsuspicious DRE. |
Senstivity | 88.5% |
Specificity | 2430% |
AUC | 0.5 |
Accuracy | NA |
Level Of Significance | NA |
Method Used | Beckman Coulter ACCESS® 2 immunoassay |
Clinical | No |
Remarks | p2PSA provides improved discrimination between prostate cancer and benign disease in screened men with a prostate specific antigen of 2.5 to 10 ng/ml and a negative digital rectal examination. |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | KLK3 |